Non-transferable risk: Difference between revisions
From ACT Wiki
Jump to navigationJump to search
imported>Doug Williamson (Layout.) |
imported>Doug Williamson (Add link.) |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 4: | Line 4: | ||
Non-transferable risks might be avoided or accepted and retained or reduced as appropriate. | Non-transferable risks might be avoided or accepted and retained or reduced as appropriate. | ||
In the case of non-transferable business risks (which by definition are not avoided) it is important that the | In the case of non-transferable business risks (which by definition are not avoided) it is important that the organisation has a distinctive competence in the relevant areas. | ||
For example, a pharmaceutical company's non-transferable risks would include the risk that failure to gain approval for use of a new drug means that the research and development costs have been wasted. | For example, a pharmaceutical company's non-transferable risks would include the risk that failure to gain approval for use of a new drug means that the research and development costs have been wasted. | ||
| Line 12: | Line 12: | ||
== See also == | == See also == | ||
* [[Committed risk]] | * [[Committed risk]] | ||
* [[Pharmaceuticals]] | |||
* [[Risk management]] | |||
* [[Transferable risk]] | * [[Transferable risk]] | ||
* [[Uncommitted risk]] | * [[Uncommitted risk]] | ||
[[Category:The_business_context]] | |||
[[Category:Identify_and_assess_risks]] | |||
[[Category:Manage_risks]] | |||
[[Category:Risk_frameworks]] | |||
[[Category:Risk_reporting]] | |||
Latest revision as of 19:58, 2 July 2021
Non-transferable risks are risks which must be borne by an organisation.
Non-transferable risks might be avoided or accepted and retained or reduced as appropriate.
In the case of non-transferable business risks (which by definition are not avoided) it is important that the organisation has a distinctive competence in the relevant areas.
For example, a pharmaceutical company's non-transferable risks would include the risk that failure to gain approval for use of a new drug means that the research and development costs have been wasted.
